Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: Mayo Clin Proc. 2018 May 24;93(7):904–916. doi: 10.1016/j.mayocp.2018.03.020

Figure 3.

Figure 3

Figure summarizing various disorders associated with telomere shortening and steps in management (Key: DKC-dyskeratosis congenita, FISH-fluorescence in-situ hybridization, TERT-telomerase reverse transcriptase, TERC-telomerase RNA component, NOP10- nuclear protein family A, member 3, NHP2- nuclear protein family A, member 2, TCAB1- Telomerase Cajal body protein 1, TIN2- TFR-1 interacting protein 2, TPP1-POT1-interacting protein, RTEL1-regulator of telomere length 1, CTC1- Conserved telomere maintenance component 1, PARN-Poly(A)-specific ribonuclease, NAF1-Nuclear Assembly Factor 1 Ribonucleoprotein, BMF-bone marrow failure, CAMT- Congenital amegakaryocytic thrombocytopenia, NCPF- non-cirrhotic portal fibrosis, NRH- nodular generative hyperplasia, SFTPC-surfactant protein C, SFTPA2-surfactant protein A2, ABCA3-ATP binding cassette subfamily A member 3, MUC5B-Mucin 5B, PAI-1-plasminogen activator inhibitor 1, MTHFR-methylenetetrahydrofolate reductase).